Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication

Randhawa, Parmjeet S.; Farasati, Noush A.; Huang, Yuchen; Mapara, Markus Y.; Shapiro, Ron
December 2010
American Journal of Clinical Pathology;Dec2010, Vol. 134 Issue 6, p916
Academic Journal
journal article
Our objective was to determine whether quantitative polymerase chain reaction (PCR) can be used to measure the effect of tyrosine kinase (TK) inhibition on polyomavirus BK (BKV) replication. The BKV was grown in a cell culture system. The rate of viral replication in the presence or absence of the drug being tested was assessed by amplifying the viral genome using primers directed against the viral capsid 1 protein. Dasatinib, erlotinib, gefitinib, imatinib, sunitinib, and sorafenib all showed antiviral activity at micromolar concentrations. The 50% effective concentration for erlotinib and sorafenib was within blood concentrations readily achieved in human subjects. Quantitative PCR is a convenient method for viral drug sensitivity testing for slow-growing viruses that do not readily produce cytopathic effect. TK inhibitors deserve further consideration as a potential therapeutic option for BKV-associated nephropathy and hemorrhagic cystitis.


Related Articles

  • Discontinuation of the Tyrosine Kinase Inhibitor Sunitinib in Patients with Metastatic Renal Cell Carcinoma: A Case Series. Neuhaus, Thomas; Luyken, Joachim; Stier, Sebastian // Urology Journal;Mar/Apr2014, Vol. 11 Issue 2, p1494 

    Purpose: Tyrosine kinase inhibitors (TKI) play a pivotal role in the modern treatment of patients with metastatic renal cell carcinoma (mRCC). Depending on the course and the response, the targeted therapy may last for years. Thus the question arises, if a successful treatment leading to a...

  • Skuldtech Readies Companion Diagnostic for TKI Masitinib. Sheridan, Cormac // BioWorld International;11/7/2012, Vol. 17 Issue 45, p1 

    The article discusses the drug masitinib, a tyrosine kinase inhibitor (TKI) developed by Skuldtech SAS, that is currently under regulatory review in 2012. A study of pancreatic cancer patients receiving masitinib and gemcitabine found an additional survival benefit of six months, while the ones...

  • microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway. Fan, Rong; Zhong, Jie; Zheng, Sichang; Wang, Zhengting; Xu, Ying; Li, Shuyi; Zhou, Jie; Yuan, Fei // Clinical & Experimental Medicine;May2015, Vol. 15 Issue 2, p137 

    To detect the expressions of microRNA-218 (miR-218) in an imatinib mesylate-sensitive human gastrointestinal stromal tumor (GIST) cells (GIST882) and an imatinib mesylate-resistant cell line (GIST430) and explore the roles of miR-218 and GIST cells in the sensitivity of gastrointestinal stromal...

  • Palbociclib: First Global Approval. Dhillon, Sohita // Drugs;Apr2015, Vol. 75 Issue 5, p543 

    Palbociclib (Ibrance) is an oral, reversible, selective, small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and CDK6 developed by Pfizer for the treatment of cancer. CDKs are important modulators of cell cycle entry and progression in response to growth signals, and inhibition of these...

  • Osimertinib: First Global Approval. Greig, Sarah // Drugs;Feb2016, Vol. 76 Issue 2, p263 

    Osimertinib (Tagrisso, AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC). Osimertinib has been designed to target the EGFR T790M...

  • Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue. Catenacci, Daniel V. T.; Liao, Wei-Li; Thyparambil, Sheeno; Henderson, Les; Xu, Peng; Zhao, Lei; Rambo, Brittany; Hart, John; Xiao, Shu-Yuan; Bengali, Kathleen; Uzzell, Jamar; Darfler, Marlene; Krizman, David B.; Cecchi, Fabiola; Bottaro, Donald P.; Karrison, Theodore; Veenstra, Timothy D.; Hembrough, Todd; Burrows, Jon // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Background: Overexpression of Met tyrosine kinase receptor is associated with poor prognosis. Overexpression, and particularly MET amplification, are predictive of response to Met-specific therapy in preclinical models. Immunohistochemistry (IHC) of formalin-fixed paraffin-embedded (FFPE)...

  • Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia. Colovic, Natasa; Tosic, Natasa; Aveic, Sanja; Djuric, Marija; Milic, Natasa; Bumbasirevic, Vladimir; Colovic, Milica; Pavlovic, Sonja // Annals of Hematology;Oct2007, Vol. 86 Issue 10, p741 

    Mutations in the fms-like tyrosine kinase 3 (FLT3) gene, such as internal tandem duplication (FLT3/ITD) in the juxtamembrane domain and point mutations in the tyrosine kinase domain, are the most common abnormalities in acute myeloid leukemia (AML). FLT3/ITD and FLT3/D835 mutations were analyzed...

  • Alectinib for First-Line Treatment in NSCLC with ALK Mutation. Kuznar, Wayne // Oncology Pharmacist;Nov2016, Vol. 9 Issue 4, p1 

    No abstract available.

  • Monitoring chronic myeloid leukemia patients responding to treatment with tyrosine kinase inhibitors by real-time quantitative polymerase chain reaction. Antolic, Margareta Radič; Zadro, Renata; Sertič, Dubravka; Labar, Boris // Biochemia Medica;Apr2009, Vol. 19 Issue 1, p63 

    Introduction: Historically, many revolutionary advances in therapy for chronic myeloid leukemia (CML) have been achieved over time, among them most important being imatinib mesylate (IM). More precise assessment of response to therapy with IM and an accurate measure of the degree of BCR-ABL...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics